Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
First received: June 5, 2007
Last updated: January 28, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||June 2013|
|Primary Completion Date:||June 2009 (Final data collection date for primary outcome measure)|
Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C. Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. Eur J Cancer. 2010 Oct;46(15):2746-52. Epub 2010 Aug 12.